Biologics are a success factor according to Lipum

News: Umeå, 23 February 2021. Article in Biostock Lipum develops a new biological drug for chronic inflammatory diseases. According to one study, the probability for approval of biological drugs is almost twice as high as that of small molecules (new molecular entities, NME). This bodes well for Lipum’s drug candidate SOL-116, which is an antibody. [...]


Lipum to carry out an IPO during 2021

News: Umeå, 19 January 2021. Article in Biostock Currently Lipum is planning an IPO (Initial Public Offering) to finance the start of the clinical trials required to take SOL-116 all the way to an approved biological drug. See this article from BioStock »  



In the magazine "Skelett och ledhälsa” our founders Professor Olle Hernell, Dr. Susanne Lindquist and Professor Lennart Lundberg were interviewed about our drug candidate SOL-116. SOL-116 is the antibody that we have developed for the treatment of chronic inflammatory diseases and we are now moving towards an IPO to secure the financing for further progress. [...]



At Biostock Life Science Summit last week our CEO Einar Pontén presented the recent progress in bringing our lead candidate SOL-116 towards clinical verification. He also briefly described Lipum’s strategy to pre-clinically explore a palette of chronic inflammatory conditions in parallel. Altogether it will constitute a solid platform for partnering and a [...]


Digital Resi – Three day conference

Lipum will participate at Digital RESI (Redefining Early Stage Investments), a dedicated global partnering event. The challenge for the attendees will be the geographic time zone issues and that may require some flexibility. Fortunately, being virtual and being able to extend the conference from a one day physical to a three-day virtual conference means more [...]


Biostock Life Science Summit

Our CEO Einar Pontén is preparing for BioStock Life Science Summit on 17 November at 12:30. He will present our unique approach to treat chronic inflammations and the progress with the lead candidate SOL-116. It has now been produced in 200L scale and is ready for toxicological studies that will start in December. In parallel [...]


Norrlandsfonden invests in lipum

Susanne Lindquist and Olle Hernell, two of Lipums founders. - Lipum is a very exciting company in drug development that also has a strong sustainability perspective, says Anna Hedström, Norrlandsfonden, in the press release published on MyNewsdesk. Read the full press release here » (in Swedish)


Next wave in Immune Therapeutics

On 29-30 September 2020, our CEO Einar Pontén together with Professor Olle Hernell will attend the virtual event by Johnson & Johnson Innovation, in collaboration with Janssen Immunology. Johnson & Johnson is seeking to gather entrepreneurs, biotech’s and academic researchers who are trying to push such boundaries for a discussion on harnessing the next wave [...]

Go to Top